Investor · 2 deals
Australian medical technology firm.
Every published round Cochlear took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| EpiMinder | Bridge / extension | 21 Mar 2022 | $16m | Participant | Startup Daily (2 Dec 2025), Startup Daily (21 Mar 2022), @AuManufacturing, Startup Daily (15 Mar 2022) | |
| Seer Medical | Series A | 2021 | $34m | Participant | Startup Daily (17 Apr 2025), SmartCompany, Startup Daily (28 Jan 2025), Startup Daily (7 Jan 2025), Startup Daily (4 Nov 2024), Giant Leap portfolio |
Companies Cochlear has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Seer Medical | Medtech company providing advanced patient monitoring and diagnostics | 2021, Series A | 1 | 0 |
| EpiMinder | Maker of a continuous seizure monitoring system for epilepsy | 21 Mar 2022, Bridge / extension | 1 | 0 |
Fund closes reported for Cochlear, as distinct from the investments it has made.
Companies Cochlear has backed that another company then bought. An exit for the holding, not a deal Cochlear did.
| Name | Role | Sources |
|---|---|---|
| Alison Deans | Chair (former) | Startup Daily (19 Mar 2024), @AuManufacturing, Startup Daily (9 Nov 2023) |
| Dr Chris Roberts | CEO (former) | SmartCompany |
| Dr Chris Roberts AO | CEO (former) | Startup Daily, @AuManufacturing |
| Tim Noakesmith | Design Lead (former) | Startup Daily (18 Jun 2025), Startup Daily (14 Jan 2025) |
| Victor Windeyer | Mechanical Engineer (former) | GBS Ventures (30 May 2007), GBS Ventures (5 Dec 2005) |
Stories naming Cochlear. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Bioshore Ventures has wrapped up its first fund at $27 million with all capital committed, drawing 65 individual backers including three well-known investors, and has named four health-technology companies in its portfolio.
An analysis of what Australian long-horizon research commercialisation requires, citing Gilmour Space, Cochlear and BluGlass as illustrations of patient capital and ecosystem support needs.
Ten13's post explains why it joined the robotics company's latest raise alongside Blackbird, Neotribe, Startmate and Horizons, covering its autonomous scanning device, dialysis focus, founders, and US rollout plans.
Profile of ARIA Research, Robert Yearsley's audio-based AR startup for blind users, recalling a $2 million NSW Medical Device Fund grant among $11 million raised and targeting the NDIS market.
Medical device firm Epiminder has joined the ASX, its shares dipping below issue price on debut, with the $125 million IPO proceeds earmarked for an American launch of its implantable epilepsy monitoring system next year.
Also Startup Daily
Biotech PolyActiva has banked a Series C round led by the National Reconstruction Fund with Brandon Capital, funding late-stage trials of its dissolvable glaucoma implant and a consolidated Melbourne site.
Also Startup Daily
Administrators confirmed a $40 million deal in which Cadwell Industries, TrialCap and Breakthrough Victoria take equity, rescuing Seer Medical from administration; the article also recalls its funding history and 2024 product recall.
Breakthrough Victoria's chief executive reflects on the sovereign fund's first four years, its university co-funding partnerships and OECD evidence that government venture capital works best alongside private investors.
Victorian epilepsy device maker Seer Medical has entered voluntary administration, with Pitcher Partners appointed amid a product recall and a cofounder's legal dispute; backers included Breakthrough Victoria and Cochlear.
Briefs roundup: Main Sequence adds Alison Deans as venture partner; Starpharma hands the CEO role to Cheryl Maley; DroneShield lands a $2.2 million repeat order; Q-CTRL will deliver quantum training with QUIN.
Main Sequence, CSIRO's deep tech venture fund, adds Cochlear chair Alison Deans as a venture partner, extending her investment committee service since 2017; its third fund brought in $450 million in July.
Weekly roundup covering six startup raises: ImmVirX, Nutromics, Nuheara, Autism 360, Cogo and Gather, plus Nutromics' 30X30 selection, a board appointment and Viralytics' earlier sale to Merck.
Wearable diagnostics developer Nutromics has raised $11 million from two unnamed family offices, after a prior $20 million round backed by Dexcom's venture arm, and appointed Dr Chris Roberts as non-executive chairperson.
Also SmartCompany·Techboard
Cardiac pacing company EBR Systems says its SOLVE-CRT trial hit its safety and efficacy goals early, keeping a 2024 US approval bid on course; the article also recalls its 2021 ASX listing.
Seer Medical founding member Dr Pip Karoly won a 2022 Prime Minister's Prize for New Innovators for seizure forecasting research; the medtech has raised over $80 million to date.
Epiminder raised A$18 million in bridge funding for its epilepsy monitoring implant, backed by existing shareholders including Cochlear, after completing an A$18 million Series A in October 2021.
Epi-Minder has completed a $16 million bridge round with its existing shareholders to fund expanded clinical trials, product development and manufacturing of its long-term epilepsy monitoring device.
Sunshine Heart's Sydney subsidiary has named Victor Windeyer general manager while he remains chief operating officer of the American-listed parent, overseeing Australian operations ahead of a planned United States clinical trial filing.
Sunshine Heart appoints Victor Windeyer as chief operating officer to lead its Australian operations and C-Pulse clinical trials from Sydney; the company also cites a secured grant and ethics approvals at two Melbourne hospitals.
Also GBS Ventures
Medtech company Sunshine Heart has brought in Ruth Flynn as its first clinical affairs manager, to drive C-Pulse heart assist device trials across Australia and New Zealand from its Sydney head office.